Biomed-valley.com

Skeptical kitten wants to see what comes out the other side. Single-asset companies. Asset-centric funds. Project-based financing. Call it what you will, but with the biopharma news flow these days, you’d think the entire industry was restructuring...

Dormant and unmonopolisable therapies: what’s the matter? In a 1981 study entitled ‘Patent-Term Extension and the Pharmaceutical Industry’, the US Congress observed that, ‘although all patented inventions receive protection for the same amount of time...

Analyst Ratings For Gilead Sciences (NASDAQ:GILD) Today, Bank of America Corp reiterated its Neutral rating on Gilead Sciences (NASDAQ:GILD) with a price target of $68.19. There are 10 hold ratings, 15 buy ratings, 1 strong buy rating on the stock...

Sanford-Burnham Medical Research Institute Announces Collaboration with Ortho-McNeil-Janssen Pharmaceuticals, Inc., to Discover New Medicines for Alzheimer’s Disease and Neuropsychiatric Disorders La Jolla, Calif. (Vocus/PRWEB) January 17, 2011 Sanford...

There are many investors who believe that the stock market is currently overvalued. To a great extent, they may be correct as there is a lot of excessive valuation to be found in various segments of the market. However, as I believe it is a market of...